Catalent and Cevec team-up to offer protein CDMO services

- Last updated on GMT

Catalent and Cevec's new protein CDMO services

Related tags: Dna, Cell

Catalent and Cevec Pharmaceuticals have joined forces to offer cell line development and manufacturing services to biotechs.

The alliance will combine Catalent’s GPEx gene-insertion tech with Cevec’s CAP cell line protein expression platform, derived from primary human aminocytes.

The deal follows a joint-study for complex protein production, which saw “record”​ yields of non-antibody proteins produced in a human expression system.

In a joint statement, the firms said they “achieved a manufacturing yield of over three grams per ltr for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative  proprietary technologies.”

Kent Payne, VP and general manager of Catalent’s biologics business said: “We look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars